Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00660504 |
Recruitment Status :
Completed
First Posted : April 17, 2008
Results First Posted : July 4, 2014
Last Update Posted : July 18, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Cancer | Drug: Amrubicin Hydrochloride Drug: Etoposide-Cisplatin combined chemotherapy | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC |
Study Start Date : | April 2008 |
Actual Primary Completion Date : | February 2012 |
Actual Study Completion Date : | August 2012 |
Arm | Intervention/treatment |
---|---|
Experimental: 1
Amrubicin Hydrochloride-Cisplatin combined chemotherapy
|
Drug: Amrubicin Hydrochloride
Amrubicin Hydrochloride combined with cisplatin |
Active Comparator: 2
Etoposide-Cisplatin combined chemotherapy
|
Drug: Etoposide-Cisplatin combined chemotherapy
combined chemotherapy |
- Overall Survival [ Time Frame: 1.5 years after last subject enrolled ]
- Progression-Free Survival [ Time Frame: 1.5 years after last subject enrolled ]
- Objective Response Rate [ Time Frame: participants were followed for the duration of the study, an average of 12 weeks ]Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
- Overall Survival at 6 and 12 Months [ Time Frame: 6 and 12 months. ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically/cytologically proven small cell lung cancer
- Extensive disease
- No prior chemotherapy regimen
- Age 18 years or older
- ECOG performance status of 0-1
Exclusion Criteria:
- Brain metastasis requiring treatment
- Treatment (Surgical or radiotherapy)of primary tumor
- Interstitial pneumonia or pulmonary fibrosis
- Abnormal cardiac function or myocardial infraction within 6 months before study enrollment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00660504
China, Fujian | |
Fuzhou, Fujian, China | |
China, Gansu | |
Lanzhou, Gansu, China | |
China, Guangdong | |
Guangzhou, Guangdong, China | |
China, Hunan | |
Changsha, Hunan, China | |
China, Jiangsu | |
Nanjing, Jiangsu, China | |
China, Jiangxi | |
Nanchang, Jiangxi, China | |
China, Jilin | |
Changchun, Jilin, China | |
China, Liaoning | |
Dalian/Shenyang, Liaoning, China | |
Shenyang, Liaoning, China | |
China, Shanxi | |
Xian, Shanxi, China | |
China, Sichuan | |
Chengdu, Sichuan, China | |
China, Zhejiang | |
Hangzhou, Zhejiang, China | |
China | |
Beijing, China | |
Shanghai, China | |
Tianjin, China |
Principal Investigator: | Yan Sun, MD | Cancer hospital, Chinese Academy of Medical Science |
Responsible Party: | Sumitomo Pharma (Suzhou) Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT00660504 |
Other Study ID Numbers: |
D0750018 D0750018 |
First Posted: | April 17, 2008 Key Record Dates |
Results First Posted: | July 4, 2014 |
Last Update Posted: | July 18, 2014 |
Last Verified: | July 2014 |
Extensive Disease-Small Cell Lung Cancer |
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Etoposide |
Amrubicin Antineoplastic Agents Antineoplastic Agents, Phytogenic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |